JP2008526750A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526750A5
JP2008526750A5 JP2007549533A JP2007549533A JP2008526750A5 JP 2008526750 A5 JP2008526750 A5 JP 2008526750A5 JP 2007549533 A JP2007549533 A JP 2007549533A JP 2007549533 A JP2007549533 A JP 2007549533A JP 2008526750 A5 JP2008526750 A5 JP 2008526750A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
peptide
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007549533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/046951 external-priority patent/WO2006078421A2/en
Publication of JP2008526750A publication Critical patent/JP2008526750A/ja
Publication of JP2008526750A5 publication Critical patent/JP2008526750A5/ja
Pending legal-status Critical Current

Links

JP2007549533A 2005-01-04 2005-12-23 脳血流を増加させる方法 Pending JP2008526750A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64141305P 2005-01-04 2005-01-04
PCT/US2005/046951 WO2006078421A2 (en) 2005-01-04 2005-12-23 Methods of increasing cerebral blood flow

Publications (2)

Publication Number Publication Date
JP2008526750A JP2008526750A (ja) 2008-07-24
JP2008526750A5 true JP2008526750A5 (https=) 2009-10-08

Family

ID=36692699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007549533A Pending JP2008526750A (ja) 2005-01-04 2005-12-23 脳血流を増加させる方法

Country Status (8)

Country Link
US (2) US7563772B2 (https=)
EP (1) EP1846016A2 (https=)
JP (1) JP2008526750A (https=)
KR (1) KR20070103009A (https=)
CN (1) CN101111257A (https=)
AU (1) AU2005325128A1 (https=)
CA (1) CA2592500A1 (https=)
WO (1) WO2006078421A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US7563772B2 (en) * 2005-01-04 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow
US20090186814A1 (en) * 2005-01-26 2009-07-23 Fumiaki Ikeno Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage
US20070066526A1 (en) * 2005-09-02 2007-03-22 Daria Mochly-Rosen Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
US7741290B2 (en) * 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
AU2007305268A1 (en) * 2006-10-02 2008-04-10 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the C2 domain of epsilon PKC, and use thereof
WO2008097563A1 (en) * 2007-02-06 2008-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-pkc inhibitor
CA2698013A1 (en) * 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
US20130274651A1 (en) 2012-04-16 2013-10-17 Denise Barbut System and method for improving outcome of cerebral ischemia

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1993007294A1 (en) * 1991-10-01 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Service A method of identifying ligands and antagonists of ligands
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5935803A (en) 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US6255057B1 (en) * 1996-07-26 2001-07-03 Ernest Gallo Clinic And Research Center Detection of cellular exposure to ethanol
WO1998017299A1 (en) * 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
WO2001028550A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
WO2001028543A1 (en) 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY
WO2001044497A2 (en) * 1999-12-02 2001-06-21 University Of Dundee Protein kinase regulation
US20020048582A1 (en) * 2000-07-18 2002-04-25 King George L. Methods of modulating angiogenesis
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20030134774A1 (en) * 2001-06-15 2003-07-17 Steinberg Susan F. Methods for inhibiting cardiac disorders
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
JP4567296B2 (ja) * 2003-03-11 2010-10-20 株式会社リコー 電子写真の画像位置検出方法およびこれを用いた記録装置
US20050164324A1 (en) * 2003-06-04 2005-07-28 Gygi Steven P. Systems, methods and kits for characterizing phosphoproteomes
WO2005107789A1 (en) * 2004-04-30 2005-11-17 The Board Of Trustees Of The Leland Stanford Junior University Use of delta pkc peptides for modulation of reactive oxigen species
US7563772B2 (en) * 2005-01-04 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow

Similar Documents

Publication Publication Date Title
Ishrat et al. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats
ES2517340T3 (es) Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
ES2765281T3 (es) Coadministración de un agente unido a un péptido de interiorización con un agente antiinflamatorio
Sredni et al. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models
CN102791279A (zh) 用于进行冠状动脉旁路移植手术的方法
CN106170491B (zh) 神经保护肽
Chugh et al. Cerebral vasospasm and delayed cerebral ischemia: Review of literature and the management approach
WO2000051623A2 (en) Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
RU2017121203A (ru) НОВЫЕ ПОЛИМЕРНЫЕ hGH ПРОЛЕКАРСТВА
RU2009128245A (ru) Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов
JP2008526750A5 (https=)
HRP20120896T1 (hr) Uporaba antagonista il-1 za lijeäśenje gihta i pseudogihta
TWI351950B (en) Use of (halobenzyloxy) benzylamino-propanamides fo
US12252554B2 (en) Analogs that target mitochondrial diseases
US10772827B2 (en) Composition for treating apoplexy through nasal administration
JPWO2020148525A5 (https=)
ES2311973T3 (es) Ctgf como objetivo para la terapia de microalbuminuria en pacientes con nefropatia diabetica.
US11571455B2 (en) Methods and compositions for treating alcoholic liver disease
JPWO2020148529A5 (https=)
JP5053665B2 (ja) 催眠用医薬組成物
Dugue et al. Controlled cortical impact-induced neurodegeneration decreases after administration of the novel calpain-inhibitor Gabadur
US20230255943A1 (en) Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
ES2366570T3 (es) Asociación de un inhibidor de la corriente if sinusal y de un inhibidor de la enzima de conversión de la angiotensina.
WO2008004653A1 (en) Prophylactic or therapeutic agent for viral disease
CN106928322A (zh) 一种具有抗脑缺血作用的融合多肽及其应用